OBJECTIVES: Our objective was to compare the measurement of residual white blood cell (rWBC) and residual red blood cell (rRBC) counts in blood products using the XN Blood Bank mode and the laboratory standard operating procedures for manual counts. In addition, to compare the whole blood complete blood count (CBC) values of blood donors and the quality of blood products using the Sysmex XN analyser versus the XS-1000i analyser. MATERIALS AND METHODS: For blood donors, 190 samples from blood or apheresis donors were analysed on both the Sysmex XS-1000i and XN-1000 analysers and the mean values of six CBC parameters were compared: the white blood cell count (WBC), the red blood cell count (RBC), haemoglobin (HGB), haematocrit (HCT), the mean corpuscular volume (MCV), the platelet count (PLT). For blood products, 164 samples were collected: 13 Plasma products - whole blood, 9 Plasma products - apheresis, 36 RBC concentrates - whole blood, 30 PLT concentrates - buffy coats, 36 PLT concentrates - buffy coats - pooled and 55 PLT concentrates - apheresis. RESULTS: All CBC parameters of the blood donors tested showed similar performance, with excellent correlation coefficients (r) ranging from 0.821 to 0.995. The majority of the blood products did not have a quantifiable number of residual cells, meaning the number of rWBC and rRBC, if present, was below the limit of quantitation (LoQ) of the different methods. rWBC were detected by Blood Bank mode in Plasma products - whole blood with a mean rWBC of 0.012 × 109 /L and in PLT concentrates - buffy coats with a mean rWBC of 0.19 × 109 /L. The correlation coefficient in both analysers for all three parameters (HGB, HCT, RBC) in RBC concentrates - whole blood was excellent, ranging from 0.95 to 0.99. For platelet count, r ranged from 0.98 to 0.99. CONCLUSION: The XN-Series analyser, equipped with a Blood Bank mode, demonstrated reliable performance when used for blood donor evaluation, rWBC enumeration and measurement of end blood products.
- MeSH
- dárci krve * MeSH
- erytrocyty MeSH
- krevní banky * MeSH
- krevní obraz metody MeSH
- lidé MeSH
- počet trombocytů MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
The WAA apheresis registry contains data on more than 140,000 apheresis procedures conducted in 12 different countries. The aim is to give an update of indications, type and number of procedures and adverse events (AEs). MATERIAL AND METHODS: The WAA-registry is used for registration of apheresis procedures and is free of charge. The responsible person for a center can apply at the site www.waa-registry.org RESULTS: Data includes reported AEs from 2012 and various procedures and diagnoses during the years 2018-2022; the latter in total from 27 centers registered a total of 9500 patients (41% women) that began therapeutic apheresis (TA) during the period. A total of 58,355 apheresis procedures were performed. The mean age was 50 years (range 0-94). The most common apheresis procedure was stem cell collection for which multiple myeloma was the most frequent diagnosis (51%). Donor cell collection was done in 14% and plasma exchange (PEX) in 28% of patients; In relation to all performed procedures PEX, using a centrifuge (35%) and LDL-apheresis (20%) were the most common. The main indication for PEX was TTP (17%). Peripheral veins were used in 56% as the vascular access. The preferred anticoagulant was ACD. AEs occurred in 2.7% of all procedures and were mostly mild (1%) and moderate 1.5% (needed supportive medication) and, only rarely, severe (0.15%). CONCLUSION: The data showed a wide range of indications and variability in apheresis procedures with low AE frequency.
- MeSH
- dárci tkání MeSH
- dítě MeSH
- dospělí MeSH
- kojenec MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- novorozenec MeSH
- plazmaferéza MeSH
- předškolní dítě MeSH
- registrace MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- separace krevních složek * metody MeSH
- výměna plazmy škodlivé účinky MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- kojenec MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
V České republice je transfuzní služba decentralizovaná a neexistuje jednotný systém sdílení dat, který by umožnil všem krevním bankám (KB) a zařízením transfuzní služby (ZTS) mít přehled o aktuální dostupnosti transfuzních přípravků (TP). Proto byl navržen systém s názvem Tržiště transfuzních přípravků pro vytvoření sdíleného pravidelně aktualizovaného přehledu o dostupnosti TP a současně je umožňoval nakupovat a prodávat v reálném čase. Společnost pro transfuzní lékařství ČLS JEP vypracovala dotazníkové šetření za účelem zjištění potřebných informací pro správné nastavení systému a jeho zavedení. Výsledky šetření po vyhodnocení došlých odpovědí ukazují, že respondenti by informační systém Tržiště transfuzních přípravků uvítali a považovali by ho za přínosný. Na základě výsledků je možné optimalizovat jednotlivé části systému tak, aby odpovídaly potřebám a požadavkům ZTS i KB, a systém tak mohl být úspěšně uveden do provozu.
The blood transfusion service in the Czech Republic is decentralized, hospital-based, and lacks a unified data-sharing system that would allow all blood banks and blood transfusion services to have an overview of the current availability of blood products (BP). Therefore, a system called the Blood Products Marketplace was designed to create a shared overview of the availability of BPs and at the same time allow them to be bought and sold in real-time thanks to regular updates. The Czech Society for Blood Transfusion created a survey in order to determine the necessary information for the correct setting of the system and its implementation. The results of the survey show that the respondents would welcome the information system of the Blood Products Marketplace and would consider it beneficial. Based on the results, it is possible to optimize individual parts of the system to meet the needs and requirements of both blood transfusion services and blood banks, and the system could be successfully put into practice.
Transfuzní přípravky potřebné pro hemoterapii v ČR vyrábějí vzájemně nezávislá zařízení transfuzní služby a poskytují je krevním bankám, které je po posouzení kompatibility vydávají jednotlivým klinickým pracovištím. Údaje o výrobě, distribuci i výdeji transfuzních přípravků v absolutních číslech jsou pravidelně shromažďovány a publikovány. Údaje o tom, zda jsou v dostatečné míře pokrývány potřeby pacientů a klinických pracovišť, však dostupné nejsou. Společnost pro transfuzní lékařství se proto obrátila na jednotlivá zařízení transfuzní služby a krevní banky s prosbou o vyplnění dotazníku zaměřeného na dostupnost transfuzních přípravků červené řady. Z analýzy získaných údajů vyplynulo, že dostupnost transfuzních přípravků červené řady je sice zajištěna, a k omezení zdravotní péče pro nedostatek potřebných transfuzních přípravků tudíž dochází zcela výjimečně, ale mnohde je tomu tak jen za cenu značného úsilí a při využití náhradních/suboptimálních postupů. Situace se přitom v průběhu let 2019–2021 zhoršovala. Varujícím ukazatelem je postupně klesající počet prvodárců, což dále snižuje stabilitu a trvalou udržitelnost systému.
Blood components needed for hemotherapy in the Czech Republic are produced by a network of independent blood establishments. Blood components are provided to hospital blood banks and, after crossmatching, issued to clinical departments. Information on production, distribution, and issue is collected and published regularly. Information on, how the needs of patients and clinical departments are met, however, is not generally available. Therefore, the Czech Society of Blood Transfusion requested transfusion services and hospital blood banks to fill in a questionnaire on the availability of red blood cell components in the years 2019–2021. Data analysis shows that the general availability of red blood cell components is guaranteed and restriction of health care due to the shortage of red blood cell components is very rare. Unfortunately, this requires great effort and the use of alternate or suboptimal procedures only. The situation slightly worsened during 2019–2021. The gradual decrease in the number of first-time donors is an additional warning signal of the decreased stability and long-term sustainability of blood transfusion services.
- MeSH
- darování krve statistika a číselné údaje MeSH
- dostupnost zdravotnických služeb statistika a číselné údaje MeSH
- konzervace krve statistika a číselné údaje MeSH
- krevní bankovnictví statistika a číselné údaje MeSH
- lidé MeSH
- průzkumy a dotazníky MeSH
- transfuze erytrocytů * statistika a číselné údaje MeSH
- zdravotnické prostředky * statistika a číselné údaje zásobování a distribuce MeSH
- Check Tag
- lidé MeSH
BACKGROUND: Leucine-rich alpha-2-glycoprotein (LRG) has been repeatedly proposed as a potential plasma biomarker for myelodysplastic syndrome (MDS). OBJECTIVE: The goal of our work was to establish the total LRG plasma level and LRG posttranslational modifications (PTMs) as a suitable MDS biomarker. METHODS: The total plasma LRG concentration was determined with ELISA, whilst the LRG-specific PTMs and their locations, were established using mass spectrometry and public mass spectrometry data re-analysis. Homology modelling and sequence analysis were used to establish the potential impact of PTMs on LRG functions via their impact on the LRG structure. RESULTS: While the results showed that the total LRG plasma concentration is not a suitable MDS marker, alterations within two LRG sites correlated with MDS diagnosis (p= 0.0011). Sequence analysis and the homology model suggest the influence of PTMs within the two LRG sites on the function of this protein. CONCLUSIONS: We report the presence of LRG proteoforms that correlate with diagnosis in the plasma of MDS patients. The combination of mass spectrometry, re-analysis of publicly available data, and homology modelling, represents an approach that can be used for any protein to predict clinically relevant protein sites for biomarker research despite the character of the PTMs being unknown.
The immune system is important for elimination of residual leukemic cells during acute myeloid leukemia (AML) therapy. Anti-leukemia immune response can be inhibited by various mechanisms leading to immune evasion and disease relapse. Selected markers of immune escape were analyzed on AML cells from leukapheresis at diagnosis (N = 53). Hierarchical clustering of AML immunophenotypes yielded distinct genetic clusters. In the absence of DNMT3A mutation, NPM1 mutation was associated with decreased HLA expression and low levels of other markers (CLIP, PD-L1, TIM-3). Analysis of an independent cohort confirmed decreased levels of HLA transcripts in patients with NPM1 mutation. Samples with combined NPM1 and DNMT3A mutations had high CLIP surface amount suggesting reduced antigen presentation. TIM-3 transcript correlated not only with TIM-3 surface protein but also with CLIP and PD-L1. In our cohort, high levels of TIM-3/PD-L1/CLIP were associated with lower survival. Our results suggest that AML genotype is related to blast immunophenotype, and that high TIM-3 transcript levels in AML blasts could be a marker of immune escape. Cellular pathways regulating resistance to the immune system might contribute to the predicted response to standard therapy of patients in specific AML subgroups and should be targeted to improve AML treatment.
- MeSH
- akutní myeloidní leukemie * diagnóza genetika MeSH
- antigeny CD274 genetika MeSH
- biologické markery MeSH
- buněčný receptor 2 viru hepatitidy A genetika MeSH
- DNA methyltransferasa 3A * genetika MeSH
- lidé MeSH
- mutace MeSH
- nukleofosmin * genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- MeSH
- ambulantní infuzní terapie * MeSH
- lidé MeSH
- paliativní péče * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- směrnice pro lékařskou praxi MeSH
- Geografické názvy
- Česká republika MeSH
- MeSH
- ambulantní infuzní terapie * MeSH
- lidé MeSH
- paliativní péče * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- směrnice pro lékařskou praxi MeSH
- Geografické názvy
- Česká republika MeSH
BACKGROUND: Extracellular vesicles are released into body fluids from the majority of, if not all, cell types. Because their secretion and specific cargo (e.g., proteins) varies according to pathology, extracellular vesicles may prove a rich source of biomarkers. However, their biological and pathophysiological functions are poorly understood in hematological malignancies. OBJECTIVE: Here, we investigated proteome changes in the exosome-rich fraction of the plasma of myelodysplastic syndrome patients and healthy donors. METHODS: Exosome-rich fraction of the plasma was isolated using ExoQuickTM: proteomes were compared and statistically processed; proteins were identified by nanoLC-MS/MS and verified using the ExoCarta and QuickGO databases. Mann-Whitney and Spearman analyses were used to statistically analyze the data. 2D western blot was used to monitor clusterin proteoforms. RESULTS: Statistical analyses of the data highlighted clusterin alterations as the most significant. 2D western blot showed that the clusterin changes were caused by posttranslational modifications. Moreover, there was a notable increase in the clusterin proteoform in the exosome-rich fraction of plasma of patients with more severe myelodysplastic syndrome; this corresponded with a simultaneous decrease in their plasma. CONCLUSIONS: This specific clusterin proteoform seems to be a promising biomarker for myelodysplastic syndrome progression.
- MeSH
- biologické markery krev MeSH
- chromatografie kapalinová MeSH
- extracelulární vezikuly metabolismus MeSH
- lidé MeSH
- myelodysplastické syndromy metabolismus patologie MeSH
- proteom analýza metabolismus MeSH
- proteomika metody MeSH
- senioři MeSH
- studie případů a kontrol MeSH
- tandemová hmotnostní spektrometrie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Liečba T-bunkami s chimérickým antigénnym receptorom (CAR T) patrí medzi najnovšie terapeutické postupy v hematoonkológii. Metóda využíva geneticky modifikované autológne T-lymfocyty, ktoré v organizme pacienta dokážu identifikovať cieľové nádorové bunky a zneškodniť ich. Anti-CD19 CAR T liečba je v súčasnosti indikovaná u detských a mladých dospelých pacientov s relabovanou alebo refraktérnou (R/R) B-akútnou lymfoblastovou leukémiou (B-ALL) a dospelých pacientov s R/R agresívnymi B-bunkovými lymfómami po dvoch alebo viacerých líniách systémovej liečby. V práci prezentujeme kazuistiku pacienta s refraktérnym difúznym veľkobunkovým B-lymfómom, u ktorého bola po zlyhaní predchádzajúcich línií protinádorovej liečby úspešne využitá CAR T terapia.
CAR T therapy, based on T-cells with the chimeric antigen receptor, represents one of the latest therapeutic approaches in haematooncology. It uses genetically modificated autologous T-lymphocytes that are able to identify and destroy target tumour cells in patient ́s organism. Today anti-CD19 CAR T therapy is indicated in children and young adults with relapsed or refractory (R/R) B-acute lymphoblastic leukaemia (B-ALL) and adult patients with R/R aggressive B-cell lymphoma after at least two lineages of immunochemotherapy. Here we present a case report of the patient with refractory diffuse large B-cell lymphoma who was successfully treated with CAR T cells.
- MeSH
- antitumorózní látky terapeutické užití MeSH
- chimerické antigenní receptory * terapeutické užití MeSH
- difúzní velkobuněčný B-lymfom * terapie MeSH
- imunologické faktory terapeutické užití MeSH
- imunoterapie adoptivní metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
